Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn’s Disease on Combination Therapy? A Multicenter Prospective Observational Study-Reference-Cited by-同舟云学术

Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn’s Disease on Combination Therapy? A Multicenter Prospective Observational Study

Published:2021-03 Issue:2 Volume:23 Page:183-194
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Pospisilova Kristyna,Siroka Jitka,Karaskova Eva,Hradsky Ondrej,Lerchova Tereza,Zarubova Kristyna,Copova Ivana,Gonsorcikova Lucie,Velganova-Veghova Maria,Francova Irena,Urbanek Lubor,Geryk Milos,Mihal Vladimir,Bronsky Jiri

Funder

Ministerstvo Zdravotnictví Ceské Republiky

OP VVV ENOCH

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology, and Child Health

Link

http://link.springer.com/content/pdf/10.1007/s40272-021-00439-1.pdf

Reference43 articles.

1. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.

2. Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterol. 2008;134(7):1861–8.

3. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, et al. Clinical trial: benefits and risks of immunomodulators and maitenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210–26.

4. Kierkus J, Iwanczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Lazowska I, et al. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60(5):580–5.

5. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanantion for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterol. 2002;122:904–15.